EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Riccardo Nevola iD, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero iD, Luca Rinaldi iD, Raffaele Marfella iD, Ferdinando Carlo Sasso iD

International Journal of Molecular Sciences · 15.01.2023 · 24 (2) · 1703

DOI: 10.3390/ijms24021703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.01.2023. Verfasst von Riccardo Nevola und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, Università Della Campania "Luigi Vanvitelli", I-80131 Naples, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 289-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorNon-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide-1 Receptor AgonistsHumansGlucagon-Like Peptide 1Liver

Stichwörter der Autor:innen

GLP-1 receptor agonistNAFLDsteatosistype 2 diabetes

Substanzen

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Advanced Medical and Surgical Sciences, Università Della Campania "Luigi Vanvitelli", I-80131 Naples, Italy.

ORCID-Profile: Riccardo Nevola, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso

Zitieren

APA

Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 24(2), 1703. https://doi.org/10.3390/ijms24021703

Vancouver

Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences. 2023;24(2):1703. doi:10.3390/ijms24021703

BibTeX
@article{Nevola2023,
  author = {Nevola, Riccardo and Epifani, Raffaella and Imbriani, Simona and Tortorella, Giovanni and Aprea, Concetta and Galiero, Raffaele and Rinaldi, Luca and Marfella, Raffaele and Sasso, Ferdinando Carlo},
  title = {GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {1703},
  doi = {10.3390/ijms24021703}
}
Kostenlos starten →